Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene
European Journal of Clinical Pharmacology(2022)
摘要
Purpose The aim of this secondary analysis was to identify prodynorphin ( PDYN ) genetic markers moderating the therapeutic response to treatment of cocaine dependence with buprenorphine/naloxone (Suboxone®; BUP). Methods Cocaine-dependent participants ( N = 302) were randomly assigned to a platform of injectable, extended-release naltrexone (XR-NTX) and one of three daily medication arms: 4 mg BUP (BUP4), 16 mg BUP (BUP16), or placebo (PLB) for 8 weeks (Parent Trial Registration: Protocol ID: NIDA-CTN-0048, Clinical Trials.gov ID: NCT01402492). DNA was obtained from 277 participants. Treatment response was determined from weeks 3 to 7 over each 1-week period by the number of cocaine-positive urines per total possible urines. Results In the cross-ancestry group, the PLB group had more cocaine-positive urines than the BUP16 group ( P = 0.0021). The interactions of genetic variant × treatment were observed in the rs1022563 A-allele carrier group where the BUP16 group ( N = 35) had fewer cocaine-positive urines ( P = 0.0006) than did the PLB group ( N = 26) and in the rs1997794 A-allele carrier group where the BUP16 group ( N = 49) had fewer cocaine-positive urines ( P = 0.0003) than did the PLB group ( N = 58). No difference was observed in the rs1022563 GG or rs1997794 GG genotype groups between the BUP16 and PLB groups. In the African American-ancestry subgroup, only the rs1022563 A-allele carrier group was associated with treatment response. Conclusion These results suggest that PDYN variants may identify patients who are best suited to treatment with XR-NTX plus buprenorphine for cocaine use disorder pharmacotherapy.
更多查看译文
关键词
Buprenorphine,Cocaine,Polymorphism,Prodynorphin,Gene
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要